Affordable Access

deepdyve-link
Publisher Website

Long-term use of fumaric acid esters for the treatment of psoriasis in daily practice.

Authors
  • Termeer, Christian1
  • Reinhold, Uwe2
  • Dirschka, Thomas3
  • von Kiedrowski, Ralph4
  • Kurzen, Hjalmar5
  • 1 Dermatology Practice, Stuttgart and Department of Dermatology, University of Freiburg, Freiburg, Germany. , (Germany)
  • 2 Department of Dermatology, Medical Center Bonn Friedensplatz, Bonn, Germany. , (Germany)
  • 3 CentroDerm Clinic Wuppertal, Germany and Faculty of Health, University Witten-Herdecke, Witten, Germany. , (Germany)
  • 4 Dermatology Practice, Selters, Germany. , (Germany)
  • 5 Dermatology Practice, Freising and Department of Dermatology, Venereology and Allergy, University Medical Center Mannheim, Ruprecht-Karls University of Heidelberg, Mannheim, Germany. , (Germany)
Type
Published Article
Journal
Journal of Dermatological Treatment
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 01, 2021
Volume
32
Issue
6
Pages
610–616
Identifiers
DOI: 10.1080/09546634.2019.1688234
PMID: 31682772
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Fumaric acid ester (FAE) is the most commonly prescribed first-line systemic therapy for the treatment of psoriasis in Germany. Although developed in the 1990s, only limited long-term data are available. Data of 200 adult psoriatic patients from 10 study centers were collected in a noninterventional, multicenter, retrospective analysis. The inclusion criteria was treatment with FAE in 2015. Eighty-two percent of the patients were naive to systemic treatment. Ten percent of all patients had FAE-treatment for 10 years or longer with an average drug survival of 4.32 years. The maintenance dose was ranging from 1-4 120 mg tablets for 87.5% of the patients. In our population, 14% of the patients stopped therapy during the first six month mainly due to gastro-intestinal side effects. No serious side effects were reported. Seventy-eight percent of the patients responded to FAE therapy with improvement of their psoriasis to mild (61%) or clear (17%). The PASI 75 response was achieved in 44% of the patient during long-term treatment without remarkable differences between moderate or severe plaque psoriasis. Our study confirms FAE therapy as a long-term, first-line treatment for moderate-to-severe plaque psoriasis.

Report this publication

Statistics

Seen <100 times